Skip to content
Screener

Alumis Inc. ALMS Accounts Payable

Accounts Payable at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$4.16B-23.4%
Amgen logo
AmgenAMGN
$2.87B-4.8%
Immunome logo
ImmunomeIMNM
$6M+28.7%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$3.35M+41.5%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$3.73M+51.4%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$73.83M+35.3%

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.52B+693%
Enterprise value$3.49B+955%
P/S418.8×

Profitability

See full
Operating margin-5,364%
Net margin-2,825.7%
FCF margin-4,487.4%

Returns & leverage

See full
Return on equity-64.6%
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Reported directly by Alumis Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.

The source filing: Alumis Inc.’s 10-Q, filed May 14, 2026.

Filed
May 14, 2026, 4:16 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001847367-26-000010
(in thousands, except share and per share amounts)March 31, 2026December 31, 2025
Total assets$671,588$411,940
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable$11,587$10,106
Research and development accrued expenses35,95934,781
Other accrued expenses and current liabilities12,58822,303
Deferred revenue, current6,3281,458
Operating lease liabilities, current4,4424,670

Item 1. Financial Statements (Unaudited)

FAQ

What is Alumis Inc.'s accounts payable?
Alumis Inc. (ALMS) reported accounts payable of $11.59M in Q1 2026.
How has Alumis Inc.'s accounts payable changed year-over-year?
Alumis Inc.'s accounts payable increased by 55.1% year-over-year, from $7.47M to $11.59M.
What is the long-term trend for Alumis Inc.'s accounts payable?
Over 2 years (2023 to 2025), Alumis Inc.'s accounts payable has grown at a 200.7% compound annual growth rate (CAGR), from $1.12M to $10.11M.
What does accounts payable mean?
Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.

Ask your AI about Alumis Inc.'s accounts payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude